{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=Janssen+Scientific+Affairs%2C+LLC", "query": { "sponsor": "Janssen Scientific Affairs, LLC", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 178, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=Janssen+Scientific+Affairs%2C+LLC&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&sponsor=Janssen+Scientific+Affairs%2C+LLC&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T14:38:35.037Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01729871", "title": "A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "rivaroxaban", "type": "DRUG" }, { "name": "uninterrupted vitamin K antagonist (VKA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 253, "start_date": "2013-02", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2017-03-06", "last_synced_at": "2026-10-11T14:38:35.037Z", "location_count": 24, "location_summary": "Beverly Hills, California • Los Angeles, California • Sacramento, California + 21 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01729871" }, { "nct_id": "NCT00585910", "title": "Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "ADHD", "Attention Deficit Hyperactivity Disorder" ], "interventions": [ { "name": "Atomoxetine and OROS Methylphenidate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 94, "start_date": "2004-01", "completion_date": "2007-12", "has_results": true, "last_update_posted_date": "2012-11-14", "last_synced_at": "2026-10-11T14:38:35.037Z", "location_count": 1, "location_summary": "Cambridge, Massachusetts", "locations": [ { "city": "Cambridge", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00585910" }, { "nct_id": "NCT03464136", "title": "Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "Placebo for Ustekinumab", "type": "BIOLOGICAL" }, { "name": "Placebo for Adalimumab", "type": "BIOLOGICAL" }, { "name": "Ustekinumab (6 mg/kg)", "type": "BIOLOGICAL" }, { "name": "Ustekinumab (90 mg)", "type": "BIOLOGICAL" }, { "name": "Adalimumab (40 mg)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 386, "start_date": "2018-03-29", "completion_date": "2021-05-21", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-10-11T14:38:35.037Z", "location_count": 67, "location_summary": "Mobile, Alabama • San Diego, California • Colorado Springs, Colorado + 60 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Bridgeport", "state": "Connecticut" }, { "city": "Danbury", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03464136" }, { "nct_id": "NCT02745054", "title": "Safety of Oral Anticoagulants Registry", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Blood Coagulation" ], "interventions": [ { "name": "mgt of bleeding concerns/complications of oral anticoagulants", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Hospital Quality Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1500, "start_date": "2016-08", "completion_date": "2018-10", "has_results": false, "last_update_posted_date": "2018-05-22", "last_synced_at": "2026-10-11T14:38:35.037Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Hartford, Connecticut • Detroit, Michigan + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Royal Oak", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02745054" }, { "nct_id": "NCT04352205", "title": "Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plasma Cell Myeloma", "Renal Failure" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2020-05-07", "completion_date": "2024-01-19", "has_results": false, "last_update_posted_date": "2024-07-01", "last_synced_at": "2026-10-11T14:38:35.037Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04352205" }, { "nct_id": "NCT01157351", "title": "15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "paliperidone", "type": "DRUG" }, { "name": "risperidone", "type": "DRUG" }, { "name": "haloperidole", "type": "DRUG" }, { "name": "perphenazine", "type": "DRUG" }, { "name": "aripiprazole", "type": "DRUG" }, { "name": "quetiapine", "type": "DRUG" }, { "name": "paliperidone palmitate", "type": "DRUG" }, { "name": "olanzapine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 450, "start_date": "2010-05", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2015-04-24", "last_synced_at": "2026-10-11T14:38:35.037Z", "location_count": 55, "location_summary": "Bullhead City, Arizona • Tuscon, Arizona • Little Rock, Arkansas + 52 more", "locations": [ { "city": "Bullhead City", "state": "Arizona" }, { "city": "Tuscon", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Escondido", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01157351" }, { "nct_id": "NCT04270175", "title": "Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Amyloid", "AL Amyloidosis", "Refractory AL Amyloidosis" ], "interventions": [ { "name": "Daratumumab SC", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2021-04-14", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-11T14:38:35.037Z", "location_count": 4, "location_summary": "Palo Alto, California • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04270175" }, { "nct_id": "NCT02187172", "title": "Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriasis", "Cardiovascular Disease" ], "interventions": [ { "name": "Ustekinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2014-07", "completion_date": "2018-09-11", "has_results": true, "last_update_posted_date": "2019-08-15", "last_synced_at": "2026-10-11T14:38:35.037Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02187172" }, { "nct_id": "NCT02951819", "title": "A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2016-11-09", "completion_date": "2020-08-17", "has_results": true, "last_update_posted_date": "2021-10-08", "last_synced_at": "2026-10-11T14:38:35.037Z", "location_count": 26, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Sedona, Arizona + 23 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02951819" }, { "nct_id": "NCT04675255", "title": "Assessing the Impact of INSTI to PI Switch on Insulin Sensitivity and Fat Metabolism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV I Infection", "Adiposity" ], "interventions": [ { "name": "Frequently sampled glucose tolerance testing", "type": "PROCEDURE" }, { "name": "abdominal subcutaneous adipose tissue biopsy", "type": "PROCEDURE" }, { "name": "MRI scan to assess intrahepatic triglyceride content", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2021-01-01", "completion_date": "2023-06-08", "has_results": false, "last_update_posted_date": "2023-08-03", "last_synced_at": "2026-10-11T14:38:35.037Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04675255" } ] }